Publication

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Ustyanovska Avtenyuk, N., Visser, N., Bremer, E. & Wiersma, V. R., 2020, In : International Journal of Molecular Sciences. 21, 21, p. 1-34 34 p., 7820.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Ustyanovska Avtenyuk, N., Visser, N., Bremer, E., & Wiersma, V. R. (2020). The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. International Journal of Molecular Sciences, 21(21), 1-34. [7820]. https://doi.org/10.3390/ijms21217820

Author

Ustyanovska Avtenyuk, Natasha ; Visser, Nienke ; Bremer, Edwin ; Wiersma, Valerie R. / The Neutrophil : The Underdog That Packs a Punch in the Fight against Cancer. In: International Journal of Molecular Sciences. 2020 ; Vol. 21, No. 21. pp. 1-34.

Harvard

Ustyanovska Avtenyuk, N, Visser, N, Bremer, E & Wiersma, VR 2020, 'The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer', International Journal of Molecular Sciences, vol. 21, no. 21, 7820, pp. 1-34. https://doi.org/10.3390/ijms21217820

Standard

The Neutrophil : The Underdog That Packs a Punch in the Fight against Cancer. / Ustyanovska Avtenyuk, Natasha; Visser, Nienke; Bremer, Edwin; Wiersma, Valerie R.

In: International Journal of Molecular Sciences, Vol. 21, No. 21, 7820, 2020, p. 1-34.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. International Journal of Molecular Sciences. 2020;21(21):1-34. 7820. https://doi.org/10.3390/ijms21217820


BibTeX

@article{05f3fbe16b0145eeabbb70f1f0b77590,
title = "The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer",
abstract = "The advent of immunotherapy has had a major impact on the outcome and overall survival in many types of cancer. Current immunotherapeutic strategies typically aim to (re)activate anticancer T cell immunity, although the targeting of macrophage-mediated anticancer innate immunity has also emerged in recent years. Neutrophils, although comprising ≈ 60% of all white blood cells in the circulation, are still largely overlooked in this respect. Nevertheless, neutrophils have evident anticancer activity and can induce phagocytosis, trogocytosis, as well as the direct cytotoxic elimination of cancer cells. Furthermore, therapeutic tumor-targeting monoclonal antibodies trigger anticancer immune responses through all innate Fc-receptor expressing cells, including neutrophils. Indeed, the depletion of neutrophils strongly reduced the efficacy of monoclonal antibody treatment and increased tumor progression in various preclinical studies. In addition, the infusion of neutrophils in murine cancer models reduced tumor progression. However, evidence on the anticancer effects of neutrophils is fragmentary and mostly obtained in in vitro assays or murine models with reports on anticancer neutrophil activity in humans lagging behind. In this review, we aim to give an overview of the available knowledge of anticancer activity by neutrophils. Furthermore, we will describe strategies being explored for the therapeutic activation of anticancer neutrophil activity.",
author = "{Ustyanovska Avtenyuk}, Natasha and Nienke Visser and Edwin Bremer and Wiersma, {Valerie R}",
year = "2020",
doi = "10.3390/ijms21217820",
language = "English",
volume = "21",
pages = "1--34",
journal = "International Journal of Molecular Sciences",
issn = "1422-0067",
publisher = "MDPI AG",
number = "21",

}

RIS

TY - JOUR

T1 - The Neutrophil

T2 - The Underdog That Packs a Punch in the Fight against Cancer

AU - Ustyanovska Avtenyuk, Natasha

AU - Visser, Nienke

AU - Bremer, Edwin

AU - Wiersma, Valerie R

PY - 2020

Y1 - 2020

N2 - The advent of immunotherapy has had a major impact on the outcome and overall survival in many types of cancer. Current immunotherapeutic strategies typically aim to (re)activate anticancer T cell immunity, although the targeting of macrophage-mediated anticancer innate immunity has also emerged in recent years. Neutrophils, although comprising ≈ 60% of all white blood cells in the circulation, are still largely overlooked in this respect. Nevertheless, neutrophils have evident anticancer activity and can induce phagocytosis, trogocytosis, as well as the direct cytotoxic elimination of cancer cells. Furthermore, therapeutic tumor-targeting monoclonal antibodies trigger anticancer immune responses through all innate Fc-receptor expressing cells, including neutrophils. Indeed, the depletion of neutrophils strongly reduced the efficacy of monoclonal antibody treatment and increased tumor progression in various preclinical studies. In addition, the infusion of neutrophils in murine cancer models reduced tumor progression. However, evidence on the anticancer effects of neutrophils is fragmentary and mostly obtained in in vitro assays or murine models with reports on anticancer neutrophil activity in humans lagging behind. In this review, we aim to give an overview of the available knowledge of anticancer activity by neutrophils. Furthermore, we will describe strategies being explored for the therapeutic activation of anticancer neutrophil activity.

AB - The advent of immunotherapy has had a major impact on the outcome and overall survival in many types of cancer. Current immunotherapeutic strategies typically aim to (re)activate anticancer T cell immunity, although the targeting of macrophage-mediated anticancer innate immunity has also emerged in recent years. Neutrophils, although comprising ≈ 60% of all white blood cells in the circulation, are still largely overlooked in this respect. Nevertheless, neutrophils have evident anticancer activity and can induce phagocytosis, trogocytosis, as well as the direct cytotoxic elimination of cancer cells. Furthermore, therapeutic tumor-targeting monoclonal antibodies trigger anticancer immune responses through all innate Fc-receptor expressing cells, including neutrophils. Indeed, the depletion of neutrophils strongly reduced the efficacy of monoclonal antibody treatment and increased tumor progression in various preclinical studies. In addition, the infusion of neutrophils in murine cancer models reduced tumor progression. However, evidence on the anticancer effects of neutrophils is fragmentary and mostly obtained in in vitro assays or murine models with reports on anticancer neutrophil activity in humans lagging behind. In this review, we aim to give an overview of the available knowledge of anticancer activity by neutrophils. Furthermore, we will describe strategies being explored for the therapeutic activation of anticancer neutrophil activity.

U2 - 10.3390/ijms21217820

DO - 10.3390/ijms21217820

M3 - Review article

C2 - 33105656

VL - 21

SP - 1

EP - 34

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1422-0067

IS - 21

M1 - 7820

ER -

ID: 141587733